Baxter develops, manufactures and markets products and therapies that save and sustain the lives of people with hemophilia, immune disorders, cancers, kidney disease, malnutrition and other acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in pharmaceuticals, biotechnology and medical devices to create products that advance patient care worldwide.
The critical condition of the ICU patient requires sage, efficient and flexible therapeutic options. Gambro has used its know how in blood purification to develop innovative concepts to offer treatments for renal and liver failure.
Maquet, a trusted partner for hospitals and physicians for more than 175 years, is a global leader in medical systems. The company offers innovative therapy solutions and infraY structure capabilities for highYacuity areas within the hospital Y including the operating room, hybrid OR, and intensive care unit Y as well as intraY and interYhospital patient transport. Additionally, Maquet develops intelligent and sustainable room concepts that exceed the expectations of modern hospitals, working in close cooperation with customers, production engineers and architects to integrate high quality products and services. Headquartered in Rastatt, Germany, Maquet is the largest subsidiary of the publicly listed Getinge Group AB of Sweden. Maquet generated about 1.55 billion Euros in 2014, representing more than half of the Getinge Group’s annual revenue of 2.93 billion Euros. Maquet has around 7,000 employees and provides 53 international sales and service organizations. Maquet is The Gold Standard. For more information, please visit www.maquet.com.
Founded more than 20 years ago in Munich Germany, Pulsion has become a leading specialist in haemodynamic monitoring and provides the clinician with a variety of technologies to optimise the haemodynamic management of patients in ICU and in the OR; transpulmonary thermodilution technique for cardiac output, preload and lung water measurements (PiCCO); fibreoptic continuous measurement of the central venous oxygen saturation via standard CVC (CeVOX); non-invasive evaluation of the liver function and splanchnic perfusion with indocyanine green dye (LiMON); non-calibrated CO trend measurement via standard arterial line (ProAQT); and the PulsioFlex monitoring platform with the modular concept to enable patient centred flexibility.